Stewart Fisher, Ph.D.

Stewart Fisher, Ph.D.

Chief Scientific OfficeratC4 Therapeutics· In proxies 2022–2023

Pay in FY2023-51% from the year before · C4 Therapeutics stock -4.2% the same year

Stewart Fisher, Ph.D. was paid $1.5M in FY2023 (Dec), down 51%. C4 Therapeutics stock fell 4.2% that year.

Pay$100 in the stock at the end of FY21 → $18
Pay is from the Summary Compensation Table of each C4 Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. C4 TherapeuticsPublic company · 4 yr
    • Chief Scientific Officer2022 – Present · 4 yrStock in role -90%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?